Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase II Pilot Trial of Bortezomib (PS-341, Velcadeãµ, IND# 58,443) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

What is the trial about?

Determine if bortezomib can be safely added to the standard COG Re-Induction therapy for relapsed ALL, and be an effective therapy.

Who can participate?

≥ 1 year of age and ≤ 31 years of age.

What is involved?

Length of study is 15 weeks. In addition to standard cancer care treatment, Minimal Residual Disease Evaluation will be performed.

Contact Nemours Clinical Trials

Trial Name: A Phase II Pilot Trial of Bortezomib (PS-341, Velcadeãµ, IND# 58,443) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)

COG#: AALL07P1

Contact Information

(800) 354-5690
clinicaltrials@nemours.org